<p>對於精明的投資者來説，被低估的生物科技股將始終具有吸引力。</p>
<p>生物科技領域正在迅速發展，製藥巨頭們不知疲倦地加強其產品線和技術。我們看到基因編輯變得更加精細，對先進醫療保健的需求不斷增長。此外，人工智能在藥物發現中的新角色可能會為生物科技公司帶來更多機會。</p>
<p>然而，這個行業可能非常波動：臨牀試驗和 FDA 批准的風險對一家公司來説是成敗的關鍵。儘管如此，這個領域為潛在的有利投資提供了激動人心的道路。</p>
<p>在正確的時間購買適當的生物科技股票可能會帶來爆炸性的收益。事實上，文章中涵蓋的股票根據分析師共識預測至少有 80% 的上漲空間。因此，現在是在這些股票持續上漲之前跟進的最佳時機。</p>
<h2>Viking 治療（VKTX）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Shutterstock</p>
<p><strong>Viking 治療</strong>（納斯達克：<strong>VKTX</strong>）可以説是新興的減肥藥市場中最具爆發力的參與者。由於其減肥候選藥 VK2735 取得了出色的成果，VKTX 股票今年迄今已飆升 168%。此外，根據 <strong>高盛</strong> 的數據，到 2030 年，減肥市場的價值可能達到約 1300 億美元，這預示着 Viking 未來有巨大的增長空間。</p>
<p>迄今為止的數據顯示，Viking 可能有重大發現。VK2735 的口服形式在第一階段試驗中僅 28 天后就顯示出了 3.3% 的體重減輕。此外，我們聽説一家制藥巨頭有可能收購該公司，這可能成為 VKTX 股票未來的主要推動因素。無論是繼續保持獨立還是以溢價價格被收購，對其股東來説未來看起來非常令人鼓舞。此外，10 位華爾街分析師將該股票評為 ‘強烈買入’，並預計有 89% 的上漲潛力。</p>
<h2>Altimmune（ALT）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：WHYFRAME / Shutterstock.com</p>
<p><strong>Altimmune</strong>（納斯達克：<strong>ALT</strong>）是另一家有前景的減肥領域參與者，可能在未來 12 個月內為投資者帶來豐厚回報。</p>
<p>在減肥領域的一小部分新興明星中，Altimmune 以其創新治療 pemvidutide 脱穎而出。根據最新試驗數據，pemvidutide 在減肥的同時幫助保持瘦體重。48 周的試驗顯示，大約 74.5% 的體重減輕與脂肪組織有關，其餘與瘦體重有關。這使 Altimmune 在競爭中佔據優勢，特別是與 GLP-1 激動劑相比，後者與更高比例的肌肉流失相關。</p>
<p>此外，該藥物在減肥之外顯示出了潛力，減少肝脂肪並治療乙型肝炎。此外，FDA 對該藥物在治療一種脂肪肝病變體的快速通道指定突顯了其潛力。因此，五位華爾街分析師將其評為 ‘強烈買入’，並預計有 171% 的強勁上漲潛力。</p>
<h2>Zura Bio（ZURA）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Shutterstock</p>
<p><strong>Zura Bio</strong>（納斯達克：<strong>ZURA</strong>）是另一家在治療免疫和炎症性疾病方面不斷取得重大進展的臨牀階段生物科技公司。與文章中討論的其他股票不同，ZURA 股票在過去一年中基本保持橫盤。然而，該股票的上漲潛力令人難以忽視，擁有三個準備進入第二階段試驗的有前途的資產。</p>
<p>其中，tibulizumab 是該公司的首選藥物候選，已進入第 II 期試驗，用於治療慢性炎症性皮膚病汗腺膿腫（HS）。此外，該候選藥將於今年晚些時候進行系統性硬皮病（SSc）的第 II 期臨牀試驗。</p>
<p>因此，通過專注於滿足免疫和炎症性疾病領域未滿足的醫療需求，Zura 在生物科技領域可能是一個重大機遇。此外，華爾街的共識預測顯示，其股價有望從當前水平上漲 478%。</p>
<p>_在發佈日期，Muslim Farooque 在本文提及的證券中沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者本人，遵守 InvestorPlace.com 的發佈準則。</p>
<p>_在發佈日期，負責編輯在本文提及的證券中沒有（直接或間接）任何持倉。</p>
<p>Muslim Farooque 是一位熱心的投資者和樂觀主義者。作為一名終身遊戲玩家和科技愛好者，他特別喜歡分析科技股。Muslim 擁有牛津布魯克斯大學應用會計學學士學位。</p>
<p>醫療保健，生物科技</p>

ZURA

Viking治療

<p>本文討論了具有突破潛力的被低估生物科技股。生物科技行業正在迅速發展，基因編輯和人工智能在藥物發現中的作用不斷取得進展。在正確的時間投資於正確的生物科技股票可能會帶來爆炸性收益。文章重點介紹了三家特定股票：Viking 治療（VKTX）、Altimmune（ALT）和 Zura Bio（ZURA），據分析師稱，每家公司都有顯著的上漲潛力。這些股票專注於減肥治療、免疫和炎症性疾病，並在其研發管線中擁有有前途的藥物候選品</p>

<p>Undervalued biotech stocks will always be relevant for the savvy investor.</p>
<div class="lb-trans"><p>對於精明的投資者來説，被低估的生物科技股將始終具有吸引力。</p>
</div><p>The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies. We’re seeing gene editing become more refined, with a growing appetite for advanced healthcare. On top of that, AI’s new role in drug discovery could take things up a notch or two for biotech players.</p>
<div class="lb-trans"><p>生物科技領域正在迅速發展，製藥巨頭們不知疲倦地加強其產品線和技術。我們看到基因編輯變得更加精細，對先進醫療保健的需求不斷增長。此外，人工智能在藥物發現中的新角色可能會為生物科技公司帶來更多機會。</p>
</div><p>However, the industry can be incredibly volatile: The stakes of clinical trials and FDA approvals are a make-or-break situation for a company, for example. Nonetheless, the landscape offers a thrilling path to potentially rewarding investments.</p>
<div class="lb-trans"><p>然而，這個行業可能非常波動：臨牀試驗和 FDA 批准的風險對一家公司來説是成敗的關鍵。儘管如此，這個領域為潛在的有利投資提供了激動人心的道路。</p>
</div><p>Snapping the right biotech stocks to buy at the right time can result in explosive gains. In fact, the stocks covered in the article offer at least an 80% upside based on analyst consensus estimates. Thus, now is the prime time to jump on these stocks before a sustained rally ahead.</p>
<div class="lb-trans"><p>在正確的時間購買適當的生物科技股票可能會帶來爆炸性的收益。事實上，文章中涵蓋的股票根據分析師共識預測至少有 80% 的上漲空間。因此，現在是在這些股票持續上漲之前跟進的最佳時機。</p>
</div><h2>Viking Therapeutics (VKTX)</h2>
<div class="lb-trans"><h2>Viking 治療（VKTX）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>來源：Shutterstock</p>
</div><p><strong>Viking Therapeutics</strong> (NASDAQ: <strong>VKTX</strong>) is arguably the most explosive entrant in the burgeoning weight loss drug market. VKTX stock has surged 168% year-to-date (YTD) due to exceptional results from its weight loss candidate, VK2735. Moreover, according to <strong>Goldman Sachs</strong>, the weight loss market could be worth roughly $130 billion by 2030, pointing to a massive growth runway ahead for Viking.</p>
<div class="lb-trans"><p><strong>Viking 治療</strong>（納斯達克：<strong>VKTX</strong>）可以説是新興的減肥藥市場中最具爆發力的參與者。由於其減肥候選藥 VK2735 取得了出色的成果，VKTX 股票今年迄今已飆升 168%。此外，根據 <strong>高盛</strong> 的數據，到 2030 年，減肥市場的價值可能達到約 1300 億美元，這預示着 Viking 未來有巨大的增長空間。</p>
</div><p>The data so far shows that Viking could be on to something huge. The oral form of VK2735 showed a 3.3% reduction in body weight after just 28 days in Phase 1 trials. Additionally, we’re hearing rumors of a pharma giant potentially acquiring the company, which could be a major catalyst for VKTX stock ahead. Whether it remains Viking independent or is snapped up at a premium price, the future looks incredibly encouraging for its shareholders. Also, 10 Wall Street analysts rate the stock as a ‘strong buy’ while projecting an 89% upside potential.</p>
<div class="lb-trans"><p>迄今為止的數據顯示，Viking 可能有重大發現。VK2735 的口服形式在第一階段試驗中僅 28 天后就顯示出了 3.3% 的體重減輕。此外，我們聽説一家制藥巨頭有可能收購該公司，這可能成為 VKTX 股票未來的主要推動因素。無論是繼續保持獨立還是以溢價價格被收購，對其股東來説未來看起來非常令人鼓舞。此外，10 位華爾街分析師將該股票評為 ‘強烈買入’，並預計有 89% 的上漲潛力。</p>
</div><h2>Altimmune (ALT)</h2>
<div class="lb-trans"><h2>Altimmune（ALT）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: WHYFRAME / Shutterstock.com</p>
<div class="lb-trans"><p>來源：WHYFRAME / Shutterstock.com</p>
</div><p><strong>Altimmune</strong>(NASDAQ: <strong>ALT</strong>) is another promising player in the weight loss sphere that could potentially reward investors handsomely over the next 12 months.</p>
<div class="lb-trans"><p><strong>Altimmune</strong>（納斯達克：<strong>ALT</strong>）是另一家有前景的減肥領域參與者，可能在未來 12 個月內為投資者帶來豐厚回報。</p>
</div><p>Among a handful of emerging stars in the weight loss niche, Altimmune stands out with its innovative treatment, pemvidutide. According to data from its latest trials, pemvidutide helped preserve lean mass while cutting weight. The 48-week trial showed that roughly 74.5% of the weight loss was linked to fat tissue, while the rest was connected to lean mass. This gives Altimmune a leg up over its competition, particularly GLP-1 agonists, which are associated with higher rates of muscle loss.</p>
<div class="lb-trans"><p>在減肥領域的一小部分新興明星中，Altimmune 以其創新治療 pemvidutide 脱穎而出。根據最新試驗數據，pemvidutide 在減肥的同時幫助保持瘦體重。48 周的試驗顯示，大約 74.5% 的體重減輕與脂肪組織有關，其餘與瘦體重有關。這使 Altimmune 在競爭中佔據優勢，特別是與 GLP-1 激動劑相比，後者與更高比例的肌肉流失相關。</p>
</div><p>Moreover, the drug has shown promise beyond weight loss, reducing liver fat, and treating hepatitis B. Additionally, the FDA’s fast-track designation for the drug in treating a variant of fatty liver disease underscores its potential. Consequently, five Wall Street analysts rate it a ‘strong buy’ and project a robust 171% upside potential.</p>
<div class="lb-trans"><p>此外，該藥物在減肥之外顯示出了潛力，減少肝脂肪並治療乙型肝炎。此外，FDA 對該藥物在治療一種脂肪肝病變體的快速通道指定突顯了其潛力。因此，五位華爾街分析師將其評為 ‘強烈買入’，並預計有 171% 的強勁上漲潛力。</p>
</div><h2>Zura Bio (ZURA)</h2>
<div class="lb-trans"><h2>Zura Bio（ZURA）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>來源：Shutterstock</p>
</div><p><strong>Zura Bio</strong> (NASDAQ: <strong>ZURA</strong>) is another clinical-stage biotech that continues to make major strides in the treatment of immune and inflammatory disorders. Unlike other stocks discussed in the article, ZURA stock has moved mostly sideways in the past year. However, the upside potential in the stock is tough to overlook, with three promising assets ready for Phase 2 trials.</p>
<div class="lb-trans"><p><strong>Zura Bio</strong>（納斯達克：<strong>ZURA</strong>）是另一家在治療免疫和炎症性疾病方面不斷取得重大進展的臨牀階段生物科技公司。與文章中討論的其他股票不同，ZURA 股票在過去一年中基本保持橫盤。然而，該股票的上漲潛力令人難以忽視，擁有三個準備進入第二階段試驗的有前途的資產。</p>
</div><p>Among these, tibulizumab is the firm’s top drug candidate, entering Phase II trials for treating hidradenitis suppurativa (HS), a chronic inflammatory skin condition. Moreover, Phase II clinical trials are scheduled for later this year for its candidate covering systemic scleroderma (SSc), a chronic autoimmune disease.</p>
<div class="lb-trans"><p>其中，tibulizumab 是該公司的首選藥物候選，已進入第 II 期試驗，用於治療慢性炎症性皮膚病汗腺膿腫（HS）。此外，該候選藥將於今年晚些時候進行系統性硬皮病（SSc）的第 II 期臨牀試驗。</p>
</div><p>Hence, Zura could potentially be a major opportunity in the biotech space through its focused approach to catering to unmet medical needs in immune and inflammatory disorders. Additionally, Wall-Street consensus estimates point to a whopping 478% upside from current levels.</p>
<div class="lb-trans"><p>因此，通過專注於滿足免疫和炎症性疾病領域未滿足的醫療需求，Zura 在生物科技領域可能是一個重大機遇。此外，華爾街的共識預測顯示，其股價有望從當前水平上漲 478%。</p>
</div><p><em>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines</em>.</p>
<div class="lb-trans"><p>_在發佈日期，Muslim Farooque 在本文提及的證券中沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者本人，遵守 InvestorPlace.com 的發佈準則。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在發佈日期，負責編輯在本文提及的證券中沒有（直接或間接）任何持倉。</p>
</div><p>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor’s of science degree in applied accounting from Oxford Brookes University.</p>
<div class="lb-trans"><p>Muslim Farooque 是一位熱心的投資者和樂觀主義者。作為一名終身遊戲玩家和科技愛好者，他特別喜歡分析科技股。Muslim 擁有牛津布魯克斯大學應用會計學學士學位。</p>
</div><p>Healthcare, Biotech</p>
<div class="lb-trans"><p>醫療保健，生物科技</p>
</div>

3 只具有突破潛力的被低估的生物科技股